✦ LIBER ✦

Emerging therapies and future directions in chronic lymphocytic leukaemia - chemotherapy

✍ Scribed by BD Cheson

Publisher: Springer
Year: 2000
Tongue: English
Weight: 202 KB
Volume: 42
Category: Article
ISSN: 1269-3286
DOI: 10.1007/s00282-000-0041-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Emerging therapies and future directions

Emerging therapies and future directions in CLL - monoclonal antibodies, vaccines and gene therapy

✍ JL Binet 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 107 KB

Detection of a hepatitis B surface antig

Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine

✍ Alexandra Alexopoulou; Spyros P. Dourakis; Helen Pandelidaki; Athanasios J. Arch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Fludarabine is used widely for the treatment of chronic lymphocytic leukaemia, but not as yet implicated in the emergence of hepatitis B surface antigen (HBsAg) variants following hepatitis B virus (HBV) reactivation. Such a variant was detected in a 78-year-old female who was HBsAg(-)/anti-HBc(+)/a

Comparison between oral and intravenous

Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome

✍ Luca Laurenti; Laura De Padua; Michela Tarnani; Nicola Piccirillo; Paolo Falcucc 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 159 KB

Phase-I/II study to evaluate dose limiti

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy

✍ T. Lissitchkov; G. Arnaudov; D. Peytchev; Kh. Merkle 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 183 KB